Sponsor Check › Person
Named as an officer, director or promoter on SEC Form D filings · NC, PA, MA, GA · Nov 12, 2009 → Nov 12, 2025
Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 3:01 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET
Clay Thorp is listed as an executive officer and director on 58 SEC Form D filings by 19 issuers between Nov 2009 and Oct 2026. Largest by amount reported sold: Hatteras Venture Partners VI, LP (Durham, NC — pooled investment fund — 2019–2020; $137.3M reported sold to 64 investors), Hatteras Venture Partners VII, LP (Durham, NC — pooled investment fund — 2023; $135.1M reported sold to 88 investors), Hatteras Venture Partners V, LP (Durham, NC — pooled investment fund — 2015; $91.1M reported sold to 34 investors), Vigil Neuroscience, Inc. (Cambridge, MA — pharmaceuticals — 2021; $90M reported sold to 19 investors), Hatteras Venture Partners IV, LP (Raleigh, NC — pooled investment fund — 2011–2012; $74.9M reported sold to 47 investors) and 14 more (all listed below).
What this means That is a lot of deals — 19 separate companies raised money with this person listed as executive officer and director, over about 17 years. Across those companies the filings report $849.8M sold in total.
Listed alongside Christy Shaffer (21 shared filings), Douglas Reed (14 shared filings), John Crumpler (12 shared filings), Robert A. Ingram (12 shared filings), Myla Lai-Goldman (9 shared filings) and 108 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Clay. Each name links to their own page.
8 of the issuers belong to the sponsor group Hatteras Venture (9 issuers, $512.7M reported sold, 2011–2026).
What this means A sponsor group is one team that sets up a new company for each deal. Hatteras Venture has 9 companies on file and $512.7M reported sold in total — the group page shows the whole track record in one place.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared the newest 50 of 58 public filings for Clay Thorp and found 14 differences, 3 worth asking the sponsor about: 4 filings report more than 10% of the money raised going to insiders; 8 Form Ds were filed more than 15 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.
Community search for Clay Thorp has not run yet — it is joining a line of 23,403 names; searches run around the clock at the hosts' allowed rate. Searched so far: 638 names.
Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).
Five things investors ask first. Items still in human review are counted, not shown.
None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 3:01 AM ET.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: VA (crawled Oct 23, 2026)
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Clay Thorp..
State securities regulators: Securities regulators searched (3,318 actions): AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE DOJ Investor Protection Unit (257 actions, 1987–2026), TX State Securities Board (586 actions, 2006–2026), WA DFI (2,039 actions, 2001–2026) — last crawled Oct 23, 2026, 9:57 PM ET. No machine-readable public listing today for CO, FL, IA, IN, MN, NE, NJ, NY, OH, UT, VA (see docs/state-regulators.md).
None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 3:01 AM ET.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons cover issuers and sponsor groups — see the issuer pages under Deals
14 differences found between the filings for Clay Thorp — 3 worth asking about (compared the newest 50 of 58 filings on Oct 24, 2026; older filings not covered)
United States Bankruptcy Court, E.D. Pennsylvania docket "Michael L. Gutch" filed Dec 16, 2011, closed Mar 23, 2012. Michael Gutch (listed on the same filings) is listed as Debtor ("Michael L. Gutch"). Our match estimate: 65%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
United States Bankruptcy Court, M.D. Pennsylvania docket "Michael C. Gutch and Maureen R. Gutch" filed Apr 15, 1991, closed Sep 17, 1991. Michael Gutch (listed on the same filings) is listed as Debtor ("Michael C. Gutch and Maureen R. Gutch"). Our match estimate: 65%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
42% of the money raised went to insiders — Clearside Biomedical, Inc. · 20% of the money raised went to insiders — ORIG3N, Inc. · 15% of the money raised went to insiders — Clearside Biomedical, Inc. · 15% of the money raised went to insiders — Clearside Biomedical, Inc.
What this means The filing reports how much of the money raised was paid to insiders. Over 10% is high for most deals. Ask what it paid for.
Hatteras Opportunity Fund I, LP (last filing Mar 7, 2024; $26,039,738 sold of $125,000,000). Each has no filing in more than two years and reported under half its target sold.
What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.
Form D filed 2,113 days after the first sale — Healthcare Innovations Venture Fund, LLC · Form D filed 366 days after the first sale — Hatteras Opportunity Fund I, LP · Form D filed 407 days after the first sale — Hatteras Venture Partners VII, LP · Form D filed 820 days after the first sale — ORIG3N, Inc. · Form D filed 42 days after the first sale — Hatteras CREATE SF SPV, LLC · and 3 more
What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.
No amendment in the last 12 months on an offering that may still be open — GeneCentric Therapeutics, Inc. (latest filing Jun 20, 2025) · No amendment in the last 12 months on an offering that may still be open — Hatteras Opportunity Fund I, LP (latest filing Mar 7, 2024) · No amendment in the last 12 months on an offering that may still be open — Hatteras Venture Partners VII, LP (latest filing Sep 8, 2023) · No amendment in the last 12 months on an offering that may still be open — GeneCentric Therapeutics, Inc. (latest filing Sep 20, 2022) · No amendment in the last 12 months on an offering that may still be open — GeneCentric Therapeutics, Inc. (latest filing Oct 7, 2021) · and 20 more
What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.
Clay Thorp appears on the Oct 17, 2013 Form D (director) but not on the Jun 23, 2014 Form D/A for the same offering.
What this means People leave, and the issuer must list only current officers, directors and promoters. It is still worth asking why this person left and who replaced them.
Offering amount changed between filings — Lysosomal Therapeutics, Inc. · Offering amount changed between filings — PhaseBio Pharmaceuticals Inc · Offering amount changed between filings — G1 Therapeutics, Inc. · Offering amount changed between filings — PhaseBio Pharmaceuticals Inc
What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.
The Jan 9, 2012 filing lists a minimum of $50,000; the Feb 16, 2012 Form D/A lists $37,499.
What this means A different minimum usually means the offering terms changed. Check which terms apply to you.
listed as "Clay Thorp" on 39 filings (from Nov 12, 2009), and "Clay B. Thorp" on 14 filings (from Sep 8, 2010).
What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.
Industry group changed between filings — Vigil Neuroscience, Inc. · Industry group changed between filings — ORIG3N, Inc. · Industry group changed between filings — PhaseBio Pharmaceuticals Inc · Industry group changed between filings — Clearside Biomedical, Inc.
What this means Often just a different box ticked; sometimes the deal changed. Ask which business your money is in.
This page covers filings where the address state is NC or PA or MA or GA. A separate record, "Clay Thorp" with address state TN, is listed on 4 filings — most recently by Pathfinder Therapeutics, Inc. (Jun 21, 2013). Both records have filings in the same period (May 27, 2010 to Jun 21, 2013).
What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.
Address moved from Durham, NC to Alpharetta, GA — Clearside Biomedical, Inc. · Address moved from Alpharetta, GA to Durham, NC — Clearside Biomedical, Inc. · Address moved from Durham, NC to Malvern, PA — PhaseBio Pharmaceuticals Inc · Address moved from Chapel Hill, NC to Research Triangle Park, NC — G1 Therapeutics, Inc. · Address moved from Durham, NC to Alpharetta, GA — Clearside Biomedical, Inc.
What this means Businesses move. If you were told one city and the forms say another, ask which is current.
NC on 38 filings (Nov 12, 2009 to Oct 14, 2026); MA on 9 filings (Feb 11, 2015 to Aug 25, 2021); PA on 4 filings (Mar 12, 2015 to Sep 10, 2018); GA on 2 filings (Oct 13, 2016 to Dec 4, 2019).
What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.
What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. We compared the newest 50 of 58 filings (work cap); older filings are not covered here. As of Oct 24, 2026.
0 of 43 offerings report sales commissions; 1 reports finder's fees totalling $118,000; 8 report proceeds to related persons totalling $3,994,205. (includes amounts the issuer reported as estimates)
| Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it | Source |
|---|---|---|---|---|---|
| Oct 14, 2026 D Hatteras Opportunity Fund II, LP File 021-601154 | $0 | $0 | $0 Other than the payment of management fees, salaries and other compensation and benefits, no partner, officer, director, manager or promoter will receive any payments from the proceeds of this offering. | None listed on this filing | EDGAR ↗ |
| Jul 20, 2026 D Healthcare Innovations Venture Fund, LLC File 021-591483 | $0 | $0 | $0 Other than the payment of management fees, salaries and other compensation and benefits, no partner, officer, director, manager or promoter will receive any payments from the proceeds of this offering. | None listed on this filing | EDGAR ↗ |
| Apr 13, 2026 D Hatteras CREATE SF SPV, LLC File 021-580086 | $0 | $0 | $0 Other than reimbursement of expenses, no officer, director, partner, manager or promoter will receive any payments from the proceeds of this offering | None listed on this filing | EDGAR ↗ |
| Nov 12, 2025 D PIPr Therapeutics, Inc. File 021-563664 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jun 20, 2025 D GeneCentric Therapeutics, Inc. File 021-549421 | $0 | $0 | $0 Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering. | None listed on this filing | EDGAR ↗ |
| Mar 7, 2024 D/A Hatteras Opportunity Fund I, LP File 021-472491 | $0 | $0 | $0 Other than the payment of management fees, salaries and other compensation and benefits, no partner, officer, director, manager, or promoter will receive any payments from the proceeds of this offering. | None listed on this filing | EDGAR ↗ |
| Sep 8, 2023 D/A Hatteras Venture Partners VII, LP File 021-472476 | $0 | $0 | $0 Other than the payment of management fees, salaries and other compensation and benefits, no partner, officer, director, manager or promoter will receive any payments from the proceeds of this offering. | None listed on this filing | EDGAR ↗ |
| Sep 20, 2022 D GeneCentric Therapeutics, Inc. File 021-459294 | $0 | $0 | $0 Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering. | None listed on this filing | EDGAR ↗ |
| Oct 7, 2021 D GeneCentric Therapeutics, Inc. File 021-416162 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Aug 25, 2021 D Vigil Neuroscience, Inc. File 021-411167 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jun 15, 2021 D/A Vigil Neuroscience, Inc. File 021-377071 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Mar 26, 2021 D StrideBio, Inc. File 021-393667 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jan 13, 2021 D GeneCentric Therapeutics, Inc. File 021-386126 | $0 | $0 | $0 Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering. | None listed on this filing | EDGAR ↗ |
| Oct 15, 2020 D/A Hatteras Venture Partners VI, LP File 021-337301 | $0 | $0 | $0 Other than the payment of management fees, and other compensation and benefits no partner, manager or promoter will receive any payments from the proceeds of this offering. | None listed on this filing | EDGAR ↗ |
| Sep 9, 2020 D ORIG3N, Inc. File 021-375084 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Dec 4, 2019 D Clearside Biomedical, Inc. File 021-354771 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 7, 2019 D Lysosomal Therapeutics, Inc. File 021-352903 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 10, 2018 D PhaseBio Pharmaceuticals Inc File 021-320911 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jun 18, 2018 D StrideBio, Inc. File 021-314778 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jan 31, 2017 D PhaseBio Pharmaceuticals Inc File 021-279697 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jan 18, 2017 D/A Lysosomal Therapeutics, Inc. File 021-233905 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jan 5, 2017 D GeneCentric Therapeutics, Inc. File 021-277741 | $0 | $0 | $0 Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering. | None listed on this filing | EDGAR ↗ |
| Oct 13, 2016 D Clearside Biomedical, Inc. File 021-272373 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Oct 6, 2016 D Lysosomal Therapeutics, Inc. File 021-272003 | $0 | $0 | $250,000 (est.) | None listed on this filing | EDGAR ↗ |
| Dec 9, 2015 D ORIG3N, Inc. File 021-252675 | $0 | $0 | $438,750 (est.) Issuer expects to use $438,750 of total amount sold as compensation for Kate Blanchard and Robin Smith and expects an additional $540,000 of total offering amount to be used as compensation for K. Blanchard and R. Smith after the remainder has been sold. | None listed on this filing | EDGAR ↗ |
| Dec 8, 2015 D Clearside Biomedical, Inc. File 021-252601 | $0 | $0 | $0 Proceeds will be used for working capital, which will include normal compensation to executive officers. | None listed on this filing | EDGAR ↗ |
| Aug 24, 2015 D Hatteras Venture Partners V, LP File 021-246318 | $0 | $0 | $0 Other than the payment of salaries and other compensation and benefits, no officer, director, manager or promoter will receive any payments from the proceeds of this offering. | None listed on this filing | EDGAR ↗ |
| Jul 21, 2015 D/A PhaseBio Pharmaceuticals Inc File 021-235733 | $0 | $0 | $900,000 (est.) | None listed on this filing | EDGAR ↗ |
| Feb 18, 2015 D ORIG3N, Inc. File 021-234278 | $0 | $0 | $305,455 (est.) The issuer expects to use $102,400 of the amount sold as compensation for Kate Blanchard and Robin Smith and expects an additional $203,055 will be used as compensation for Kate Blanchard and Robin Smith after the remainder has been sold. | None listed on this filing | EDGAR ↗ |
| Feb 12, 2015 D G1 Therapeutics, Inc. File 021-233991 | $0 | $0 | $0 Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering. | None listed on this filing | EDGAR ↗ |
| Sep 15, 2014 D Clearside Biomedical, Inc. File 021-224726 | $0 | $118,000 | $550,000 (est.) | None listed on this filing | EDGAR ↗ |
| Jul 11, 2014 D/A GeneCentric Therapeutics, Inc. File 021-198924 | $0 | $0 | $0 Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering. | None listed on this filing | EDGAR ↗ |
| May 12, 2014 D Clearside Biomedical, Inc. File 021-217166 | $0 | $0 | $450,000 (est.) | None listed on this filing | EDGAR ↗ |
| Oct 17, 2013 D G1 Therapeutics, Inc. File 021-204775 | $0 | $0 | $0 Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering. | None listed on this filing | EDGAR ↗ |
| Aug 23, 2013 D/A G1 Therapeutics, Inc. File 021-195183 | $0 | $0 | $0 Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering. | None listed on this filing | EDGAR ↗ |
| Feb 12, 2013 D Clearside Biomedical, Inc. File 021-191713 | $0 | $0 | $600,000 (est.) | None listed on this filing | EDGAR ↗ |
| Dec 28, 2012 D/A Hatteras Venture Partners IV, LP File 021-164902 | $0 | $0 | $0 Other than the payment of salaries and other compensation and benefits no officer, director, or promoter will receive any payments from the proceeds of this offering. | None listed on this filing | EDGAR ↗ |
| Jun 18, 2012 D/A PhaseBio Pharmaceuticals Inc File 021-40668 | $0 | $0 | $0 Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering. | None listed on this filing | EDGAR ↗ |
| Feb 16, 2012 D/A Clearside Biomedical, Inc. File 021-171400 | $0 | $0 | $500,000 (est.) | None listed on this filing | EDGAR ↗ |
| Sep 23, 2010 D/A ArtusLabs Inc File 021-147436 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 23, 2010 D/A ArtusLabs Inc File 021-147437 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Aug 9, 2010 D/A ArtusLabs Inc File 021-110610 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Mar 25, 2010 D/A CancerGuide Diagnostics, Inc. File 021-138168 | $0 | $0 | $0 Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering. | None listed on this filing | EDGAR ↗ |
Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
Every issuer that named Clay Thorp on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.
Raised $22.3M from 21 investors (22% of the $100M target) as of the latest filing. Clay is listed as executive officer.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $25M from 2 investors (20% of the $125M target) as of the latest filing. Clay is listed as executive officer.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $737K from 2 investors (25% of the $3M target) as of the latest filing. Clay is listed as executive officer.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Investing / 506(b) (2,521 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $18.9M from 7 investors (100% of the $2.5M target) as of the latest filing. Clay is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $6.11M from 9 investors (100% of the $5M target) as of the latest filing. Clay is listed as director on 7 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $26M from 31 investors (21% of the $125M target) as of the latest filing. Clay is listed as executive officer on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $135.1M from 88 investors (54% of the $250M target) as of the latest filing. Clay is listed as executive officer on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $90M from 19 investors (100% of the $90M target) as of the latest filing. Clay is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $48.9M from 17 investors (60% of the $81.5M target) as of the latest filing. Clay is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $137.3M from 64 investors (55% of the $250M target) as of the latest filing. Clay is listed as executive officer on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $26.2M from 11 investors (91% of the $28.7M target) as of the latest filing. Clay is listed as director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $16.2M from 31 investors (100% of the $3.35M target) as of the latest filing. Clay is listed as director on 8 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $26.1M from 11 investors (100% of the $3M target) as of the latest filing. Clay is listed as director on 4 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $48.5M from 20 investors (100% of the $32.1M target) as of the latest filing. Clay is listed as director on 8 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $91.1M from 34 investors (61% of the $150M target) as of the latest filing. Clay is listed as executive officer.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $50M from 21 investors (100% of the $33M target) as of the latest filing. Clay is listed as director on 4 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $74.9M from 47 investors (60% of the $125M target) as of the latest filing. Clay is listed as executive officer on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $3.68M from 10 investors (100% of the $600K target) as of the latest filing. Clay is listed as director on 5 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $2.75M from 5 investors (26% of the $10.5M target) as of the latest filing. Clay is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.
Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.
Listed on the same filings as Clay Thorp. Their page shows their other deals.
Listed on the same filings as Clay Thorp. Their page shows their other deals.
Listed on the same filings as Clay Thorp. Their page shows their other deals.
Listed on the same filings as Clay Thorp. Their page shows their other deals.
Listed on the same filings as Clay Thorp. Their page shows their other deals.
Listed on the same filings as Clay Thorp. Their page shows their other deals.
Christy Shaffer is on 18 issuers in total — a repeat sponsor. Their page lists every one.
Douglas Reed is on 17 issuers in total — a repeat sponsor. Their page lists every one.
Robert A. Ingram is on 9 issuers in total — a repeat sponsor. Their page lists every one.
John Crumpler is on 16 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Clay Thorp. Their page shows their other deals.
Michael Dial is on 8 issuers in total — a repeat sponsor. Their page lists every one.
Asish Xavier is on 22 issuers in total — a repeat sponsor. Their page lists every one.
Bruce Booth is on 21 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Clay Thorp. Their page shows their other deals.
James Barrett is on 7 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Clay Thorp. Their page shows their other deals.
David S. Jones is on 5 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Clay Thorp. Their page shows their other deals.
Robert Carpenter is on 6 issuers in total — a repeat sponsor. Their page lists every one.
One team, 9 deal companies. Clay Thorp is listed on 8 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Clay Thorp.
A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.
A person is never an adviser firm. 5 of the 19 issuers this person is listed on match a Form ADV adviser (searched 24,962 advisers as of Oct 2, 2026): Healthcare Innovations Venture Fund, LLC, Hatteras CREATE SF SPV, LLC, Hatteras Opportunity Fund I, LP, Hatteras Venture Partners VII, LP, Hatteras Venture Partners V, LP.
Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.
Property records are matched to companies only, never to individuals, so none are matched to Clay Thorp by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 19 issuers this person is listed on — nothing matched.
Websites and social links of the issuers Clay Thorp is listed on: none on file. No website or social profile named in Hatteras Venture Partners VII, LP's SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #117,085 of 374,652 in line (1,174 issuers searched so far). One-tap searches: Look further ↓
One-tap searches on sites we do not index ourselves, with the name pre-filled (Durham, NC). Each opens in a new tab; what you find there is not verified by PartnerFacts.
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Clay Thorp appears on a new Form D, or when a court case or SEC action is matched to them. See plans →
